Funded Health Care Startups in Philadelphia
Across the 17 most recent disclosed health care rounds in Philadelphia, the largest disclosed amount is Ballers’ $20M Series A on 2025-06-09.
Across the 17 most recent disclosed health care rounds in Philadelphia, the largest disclosed amount is Ballers’ $20M Series A on 2025-06-09. That $20M sits far above most other disclosed rounds in the list, where the next-largest disclosed figures are in the $12M range (Impilo $12M on 2024-11-14; Ritten $12M on 2024-05-29) and several others cluster at $10M–$4M (Vitara Biomedical $10M on 2024-10-28; Vybe $9M on 2023-10-16; NeuroFlow and Bainbridge Health both $3M in May 2025).
The timing shows a concentration in the most recent half-year: 3 of 17 rounds are dated between 2025-05-08 and 2025-06-09 (NeuroFlow $3M on 2025-05-15; Bainbridge Health $3M on 2025-05-08; Ballers $20M on 2025-06-09). Stage disclosure is also skewed toward nonstandard labels: 4 of 17 rows are “Series Unknown” and 1 is “undisclosed,” while the disclosed “Series A” rounds include Ballers ($20M), Impilo ($12M), and Ritten ($12M). Rounds span 2021-12-14 (RoundTrip) through 2025-06-09 (Ballers).
Most recent rounds
17 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Philadelphia health care set, and how does it compare to the rest of the disclosed amounts?
Ballers’ $20M Series A (2025-06-09) is the only disclosed round in the $20M range, and it dwarfs most other disclosed amounts. The next-largest disclosed figures are $12M (Impilo $12M on 2024-11-14; Ritten $12M on 2024-05-29), with several entries clustering at $10M–$4M (e.g., Vitara Biomedical $10M on 2024-10-28; Vybe $9M on 2023-10-16; Cayaba Care $4M on 2024-03-13).
Do multiple rounds cluster in a narrow date window near the top of the list?
Yes. Three of the 17 rows fall within roughly one month in May–June 2025: Bainbridge Health closed $3M on 2025-05-08, NeuroFlow closed $3M on 2025-05-15, and Ballers closed $20M on 2025-06-09. Beyond that, other notable clusters appear in 2024 (e.g., two $12M-class rounds: Impilo on 2024-11-14 and Ritten on 2024-05-29, plus $10M on 2024-10-28).
How much of the stage/amount reporting is nonstandard (Series Unknown or undisclosed), and what does that mean for interpretability?
5 of 17 rows use nonstandard amount labels: 4 are “Series Unknown” with amounts shown (e.g., NeuroFlow $3M on 2025-05-15; Bainbridge Health $3M on 2025-05-08; Vitara Biomedical $10M on 2024-10-28; Vybe $9M on 2023-10-16), and 1 is explicitly “undisclosed” (Sena Health on 2023-01-12). That means most entries provide economics, but fewer provide consistent stage comparability.
Which stage label dominates where it is disclosed, and how concentrated are the “Series A” amounts?
Where a standard stage label appears, “Series A” is concentrated in three disclosed rounds: Ballers $20M (2025-06-09), Impilo $12M (2024-11-14), and Ritten $12M (2024-05-29). Together these three “Series A” rounds account for the highest disclosed amounts in the table, all above the $10M mark only on Ballers’ $20M.
Are there outliers at the low end worth flagging alongside the top-end outlier?
At the low end, Vasowatch’s $30K pre-seed (2023-04-24) is the smallest disclosed amount in the list, far below other small rounds like Eztia’s $10K (2023-04-13) and Vital Start Health’s $20K (2022-11-22). On the other side, Ballers’ $20M (2025-06-09) is the single high-end outlier, creating a wide spread between early-stage and the largest disclosed financings.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.